IL13 critically contributes to the antitumor activity of polyfunctional CD4+ T cells driven by constitutively active Stat5

IL13 is a critical effector cytokine for the antitumor activity of CASTAT5-conditioned polyfunctional CD4+ T cells, with IL13 disruption impairing tumor control in mouse models.

• Why it matters: Polyfunctional CD4 T cells correlate with better cancer outcomes, but the specific effector mechanisms behind CASTAT5-driven antitumor effects were unclear.
• What they did: CASTAT5-modified C5-CD4 cells showed a Th2 cytokine program and extensive epigenomic remodeling at Th2 loci (Hi-C, CUT&Tag); IL13 was tested by neutralization and targeted Il13 disruption, including in a CD19-targeted CAR-T mouse B-cell lymphoma model.
• The result: Blocking or disrupting IL13 reduced donor T cell expansion and persistence, weakened systemic cytokine/chemokine responses, attenuated endogenous tumor-reactive CD8 activation, and diminished CASTAT5 CD19CAR-T efficacy; IL13 expression also associated with type 2 signatures linked to prolonged response in a human CD19CAR-T infusion-product dataset.

AI summary of the abstract · may contain errors · not medical advice · read the paper.